Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Appealing Doan's Pills FTC $8 Mil. Corrective Ad Order

This article was originally published in The Tan Sheet

Executive Summary

Novartis plans to "file an appeal with a federal court" contesting the Federal Trade Commission's May 27 order requiring corrective advertising and labeling for Doan's Pills ad claims. In a 4-0 vote, the commission reversed a March 1998 administrative law judge's decision not to impose corrective advertising to remedy what FTC charges were deceptive superiority claims.

You may also be interested in...



Doan's FTC Correction Requirement Is "Punitive" And "Irrational" - Novartis

Novartis is asking the Federal Trade Commission to stay the corrective advertising requirement in FTC's final order in the case regarding Doan's Pills advertising claims. The firm asserts FTC's requirement for corrective ad copy is punitive in nature and "irrational" in its application for a stay of Part IV of the commission's final order and decision. FTC had concluded certain superiority claims used in Doan's ads were deceptive.

Doan's FTC Correction Requirement Is "Punitive" And "Irrational" - Novartis

Novartis is asking the Federal Trade Commission to stay the corrective advertising requirement in FTC's final order in the case regarding Doan's Pills advertising claims. The firm asserts FTC's requirement for corrective ad copy is punitive in nature and "irrational" in its application for a stay of Part IV of the commission's final order and decision. FTC had concluded certain superiority claims used in Doan's ads were deceptive.

Doan's FTC Correction Requirement Is "Punitive" And "Irrational" - Novartis

Novartis is asking the Federal Trade Commission to stay the corrective advertising requirement in FTC's final order in the case regarding Doan's Pills advertising claims. The firm asserts FTC's requirement for corrective ad copy is punitive in nature and "irrational" in its application for a stay of Part IV of the commission's final order and decision. FTC had concluded certain superiority claims used in Doan's ads were deceptive.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS089879

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel